|Place of Origin:||China|
|Certification:||CE FDA TGA|
|Minimum Order Quantity:||10000pcs|
|Packaging Details:||25tests/box 1test/box|
|Delivery Time:||5-20 days|
|Payment Terms:||T/T, Western Union, MoneyGram|
|Sample Collection:||Nasal Swab||Package:||25pcs/box, 1pcs/box|
|Use:||Fast Check Of Coronavirus||Reading Time:||In 15 Mins|
|Method:||Colloidal Gold Assay||Qualitative:||Qualitative Determination Of Covid-19|
The Test Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from 2019-nCoV in saliva specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset.
Results are for the identification of 2019-nCoV nucleocapsid protein antigen. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results should be treated as presumptive, and do not rule out 2019-nCoV infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.
SUMMARY AND EXPLANATION
The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
|48 Rxns||96 Rxns|
|1||Nucleic acid release agent||1.4mL/tube||2 tubes||5.3 mL/bottle||1 bottle||Surfactant|
|2||RNA protectant||27 μL/tube||1 tube||53 μL/tube||1 tube||RNase inhibitor|
|3||SARS-CoV-2 reaction solution||800 μL/tube||1 tube||1600 μL/tube||1 tube||Primer, probe, reaction buffer, dNTP|
|4||SARS-CoV-2 enzyme mixture||80 μL/tube||1 tube||160 μL/tube||1 tube||Hot start Taq enzyme, M-MLV enzyme|
|5||SARS-CoV-2 positive control||100 μL/tube||1 tube||100 μL/tube||1 tube||Recombinant plasmid containing target fragment, RNA|
|6||SARS-CoV-2 negative control||1200 μL/tube||1 tube||1200 μL/tube||1 tube||TE buffer|
Easy specimen collection
Fast results in 15 minutes assay time
Easy visually interpretation
Simple operation, no equipment required
HOW TO PERFORM THE TEST?
1. Remove a Test Device from the foil pouch by tearing at the notch and place it on a level surface.
2. Holding Extraction Reagent bottle vertically, add 10 drops (400μL) to the Extraction tube.
3. Insert the nasopharyngeal (and oropharyngeal) swab sample(s) into the extraction solution, then, mix the swab 10 times.
4. Remove the swabs while pressing against the solution tube in order to extract most of the specimen
5. Place the dropper cap and drop 3 drops (60~70μl) into the sample well.
6. Read the result in 10-15 minutes. Do not read results after more than 20 minutes.
Something you need to learn about:
1) What is the difference between an antigen test and a molecular test?
An antigen test detects specific proteins on the surface of the virus. These tests are quicker and less expensive, but have a higher chance of missing an active infection, according to the FDA.
A molecular (PCR or polymerase chain reaction) test detects the virus’s genetic material. These tests require a more complex technology to get results, and it usually takes a day or two to get those results (depending on lab capacity, results may take up to a week).
If an antigen test shows a negative result and you have reason to believe you may have the virus (because of symptoms or exposure), your doctor may order a molecular test to confirm the results.
2) Which tests are more accurate?
No test is 100% accurate, but the molecular tests are considered to be more accurate than the antigen tests, according to available research.
According to the FDA, an antigen test cannot “definitively rule out active coronavirus infection,” but positive results are “highly accurate” (negative results may require a confirmation test).
Harvard Medical School wrote in August that the reported rate of false negatives with molecular testing is as low as 2% and as high as 37%. A molecular test using a deep nasal swab will have fewer false negative results than samples from throat swabs or saliva, they say.
For antigen testing, Harvard noted that the reported rate of false negative results can be as high as 50%, but that the FDA has granted emergency use authorization for a more accurate antigen test.
In general, some of the issues that may affect the accuracy of a test include ineffective swabbing, contamination or mishandling of the sample, or problems with the testing chemicals, according to the FDA.
3) If antigen tests are less accurate, why would we use them?
Experts say the value in the rapid antigen tests is in the frequency of the testing rather than the accuracy, with repeated testing recommended. According to Science, getting a false negative in an antigen test two or three times in a row is rare. This strategy lines up with the NPR report mentioned above, which would employ daily testing of those in high-risk areas.
4) Who must be tested for COVID-19?
As per the Minister’s Directive: COVID-19: Long-Term Care Home Surveillance Testing and Access to Homes (Minister’s Directive) effective January 8, 2021, all staff, student placement and volunteers working in long-term care homes must be tested regularly in accordance with the Minister’s Directive, unless the exception for individuals who have previously had laboratory confirmed COVID-19 applies. The testing requirements in the Minister’s Directive include all individuals working in long-term care homes who are: • Staff as defined in the Long-Term Care Homes Act, 2007 • Volunteers as defined in the Long-Term Care Homes Act, 2007 • Student placement, meaning any person working in the long-term care home as part of a clinical placement requirement of an educational program of a college or university, and who does not meet the definition of “staff” or “volunteer” under the Long-Term Care Homes Act, 2007. The Minister’s Directive also includes additional testing and documentation requirements for general visitors, caregivers and support workers.